Maze Therapeutics (NASDAQ:MAZE) Trading 8.4% Higher – Here’s What Happened

Maze Therapeutics, Inc. (NASDAQ:MAZE) was up 8.4% during mid-day trading on Wednesday . The stock traded as high as $36.50 and last traded at $36.02. Approximately 328,145 shares were traded during trading, an increase of 6% from the average daily volume of 308,758 shares. The stock had previously closed at $33.23.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on the company. JPMorgan Chase & Co. lifted their price objective on Maze Therapeutics from $27.00 to $37.00 and gave the stock an “overweight” rating in a report on Monday, September 29th. Guggenheim raised their price target on Maze Therapeutics from $19.00 to $34.00 and gave the stock a “buy” rating in a research report on Monday, September 15th. Weiss Ratings reiterated a “sell (d)” rating on shares of Maze Therapeutics in a research report on Wednesday, October 8th. Wedbush raised their target price on shares of Maze Therapeutics from $35.00 to $36.00 and gave the stock an “outperform” rating in a report on Friday, November 7th. Finally, Raymond James Financial started coverage on shares of Maze Therapeutics in a research note on Thursday, November 13th. They issued an “outperform” rating and a $48.00 target price on the stock. Two investment analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $38.57.

Maze Therapeutics Stock Performance

The business has a 50-day simple moving average of $28.24 and a 200 day simple moving average of $18.46. The firm has a market cap of $1.70 billion and a P/E ratio of -1.69.

Maze Therapeutics (NASDAQ:MAZE) last posted its earnings results on Thursday, November 6th. The company reported ($0.66) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.74) by $0.08.

Insider Buying and Selling

In other news, Director Richard H. Scheller sold 20,744 shares of the firm’s stock in a transaction dated Monday, September 15th. The shares were sold at an average price of $22.37, for a total value of $464,043.28. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Hedge Funds Weigh In On Maze Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. New York State Common Retirement Fund purchased a new stake in Maze Therapeutics in the first quarter worth about $25,000. CWM LLC purchased a new position in shares of Maze Therapeutics during the 2nd quarter worth approximately $28,000. Ameritas Investment Partners Inc. raised its position in shares of Maze Therapeutics by 82.6% in the 3rd quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company’s stock worth $42,000 after acquiring an additional 738 shares in the last quarter. Corebridge Financial Inc. purchased a new position in shares of Maze Therapeutics in the 1st quarter valued at approximately $48,000. Finally, Russell Investments Group Ltd. lifted its stake in shares of Maze Therapeutics by 947.8% in the 3rd quarter. Russell Investments Group Ltd. now owns 1,907 shares of the company’s stock valued at $49,000 after purchasing an additional 1,725 shares during the period.

Maze Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.